全文获取类型
收费全文 | 902400篇 |
免费 | 76184篇 |
国内免费 | 4994篇 |
专业分类
耳鼻咽喉 | 13208篇 |
儿科学 | 25165篇 |
妇产科学 | 25513篇 |
基础医学 | 128229篇 |
口腔科学 | 26116篇 |
临床医学 | 80629篇 |
内科学 | 169875篇 |
皮肤病学 | 17300篇 |
神经病学 | 71881篇 |
特种医学 | 36640篇 |
外国民族医学 | 182篇 |
外科学 | 140217篇 |
综合类 | 34028篇 |
现状与发展 | 15篇 |
一般理论 | 267篇 |
预防医学 | 70095篇 |
眼科学 | 21587篇 |
药学 | 69272篇 |
53篇 | |
中国医学 | 5100篇 |
肿瘤学 | 48206篇 |
出版年
2018年 | 8790篇 |
2016年 | 7797篇 |
2015年 | 9702篇 |
2014年 | 13673篇 |
2013年 | 19220篇 |
2012年 | 25977篇 |
2011年 | 27504篇 |
2010年 | 16617篇 |
2009年 | 15372篇 |
2008年 | 25149篇 |
2007年 | 27023篇 |
2006年 | 26667篇 |
2005年 | 26035篇 |
2004年 | 25179篇 |
2003年 | 24262篇 |
2002年 | 23134篇 |
2001年 | 36793篇 |
2000年 | 37229篇 |
1999年 | 31548篇 |
1998年 | 9599篇 |
1997年 | 8997篇 |
1996年 | 8761篇 |
1995年 | 8284篇 |
1994年 | 7946篇 |
1992年 | 26782篇 |
1991年 | 26211篇 |
1990年 | 25703篇 |
1989年 | 24767篇 |
1988年 | 23283篇 |
1987年 | 22937篇 |
1986年 | 21775篇 |
1985年 | 21126篇 |
1984年 | 16396篇 |
1983年 | 14004篇 |
1982年 | 8860篇 |
1981年 | 8205篇 |
1980年 | 7674篇 |
1979年 | 16738篇 |
1978年 | 12114篇 |
1977年 | 10181篇 |
1976年 | 9328篇 |
1975年 | 10147篇 |
1974年 | 12641篇 |
1973年 | 12136篇 |
1972年 | 11538篇 |
1971年 | 10685篇 |
1970年 | 10218篇 |
1969年 | 9909篇 |
1968年 | 8900篇 |
1967年 | 8230篇 |
排序方式: 共有10000条查询结果,搜索用时 62 毫秒
61.
William G. Breen Krishan R. Jethwa Nathan Y. Yu Grant M. Spears William S. Harmsen Robert C. Miller Jonathan B. Ashman William G. Rule Terence T. Sio Michelle A. Neben-Wittich Michael G. Haddock Amit Mahipal Mark J. Truty Christopher L. Hallemeier Kenneth W. Merrell 《Practical radiation oncology》2021,11(1):e63-e69
PurposeOur purpose was to determine the effect of chemoradiotherapy (CRT) on patient-reported quality of life (QOL) for patients with intact pancreas cancer.Methods and MaterialsWe reviewed a prospective QOL registry for patients with intact, clinically localized pancreatic ductal adenocarcinoma treated with CRT between June 2015 and November 2018. QOL was assessed pre-CRT (immediately before CRT, after neoadjuvant chemotherapy) and at the completion of CRT with the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) and its component parts: FACT-General (FACT-G) and hepatobiliary cancer subscore (HCS). A minimally important difference from pre-CRT was defined as ≥ 6, 5, and 8 points for FACT-G, HCS, and FACT-Hep, respectively.ResultsOf 157 patients who underwent CRT, 100 completed both pre- and post-CRT surveys and were included in the primary analysis. Median age at diagnosis was 65 years (range, 23-90). National Comprehensive Cancer Network resectability status was resectable (3%), borderline resectable (40%), or locally advanced (57%). Folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) (75%) or gemcitabine and nab-paclitaxel (42%) were given for a median of 6 cycles (range, 0-42) before CRT. Radiation therapy techniques included 3-dimensional conformal (22%), intensity modulated photon (55%), and intensity modulated proton (23%) radiation therapy to a median dose of 50 Gy (range, 36-62.5). Concurrent chemotherapy was most commonly capecitabine (82%). Sixty-three patients (63%) had surgery after CRT. The mean decline in FACT-G, HCS subscale, and FACT-Hep from pre- to post-CRT was 3.5 (standard deviation [SD], 13.7), 1.7 (SD 7.8), and 5.2 (SD 19.4), respectively. Each of these changes were statistically significant, but did not meet the minimally important difference threshold. Pancreatic head tumor location was associated with decline in FACT-Hep. Nausea was the toxicity with the greatest increase from pre- to post-CRT by both physician-assessment and patient-reported QOL.ConclusionsFor patients with intact pancreatic adenocarcinoma, modern CRT is well tolerated with minimal decline in QOL during treatment. 相似文献
62.
The retroviral protease of human immunodeficiency virus (HIV) is an excellent target for antiviral inhibitors for treating HIV/AIDS. Despite the efficacy of therapy, current efforts to control the disease are undermined by the growing threat posed by drug resistance. This review covers the historical background of studies on the structure and function of HIV protease, the subsequent development of antiviral inhibitors, and recent studies on drug-resistant protease variants. We highlight the important contributions of Dr. Stephen Oroszlan to fundamental knowledge about the function of the HIV protease and other retroviral proteases. These studies, along with those of his colleagues, laid the foundations for the design of clinical inhibitors of HIV protease. The drug-resistant protease variants also provide an excellent model for investigating the molecular mechanisms and evolution of resistance. 相似文献
63.
目的:探讨miR-26b参与原发性肝细胞肝癌(HCC)侵袭的机制。方法:在细胞培养液中培养人肝细胞系HL-7702和HCC细胞各系Hepb-3、HuH-7、MHCC97-L、MHCC97-H。实时荧光定量PCR法(qRT-PCR)检测miR-26b的表达水平;用miR-26b mimics、miR-26b inhibitors和Notch1-siRNA分别转染HCC细胞;MTT实验检测转染后HCC细胞的活力;采用Western blot检测Notch1受体蛋白表达水平的变化;Transwell小室测定不同处理后的HCC细胞的侵袭能力。结果:人正常肝细胞系HL-7702和HCC细胞系Hepb-3、HuH-7、MHCC97-L、MHCC97-H中的miR-26b相对表达含量随其侵袭和迁移能力的升高而依次下降;抑制miR-26b的表达,Notch1受体蛋白表达明显增高,而此时HCC细胞的侵袭性显著增强;相反,上调miR-26b的表达,Notch1受体蛋白表达明显降低,而HCC细胞侵袭性显著下降;miR-26b可能通过调控Notch1信号通路调节HCC细胞侵袭性。结论:miR-26b通过负调控Notch1信号通路抑制HCC细胞侵袭能力,为HCC侵袭的机制奠定了理论基础,miR-26b可能成为HCC治疗的新靶点。 相似文献
64.
65.
66.
67.
随着腔镜技术的进一步发展以及微创理念应用于结直肠外科疾病的诊治中,结直肠相关疾病的诊治发生了翻天覆地的变化。由传统的经腹手术到腹腔镜手术、经自然腔道手术,再到经自然腔道取标本手术(NOSES),结直肠疾病的外科诊治在微创领域取得了巨大成果。NOSES技术是目前结直肠外科在微创领域前沿的手术方式之一,它通过经直肠、阴道取标本来避免了腹壁的辅助取标本切口,从而将结直肠外科手术进一步微创化。NOSES技术集传统腹腔镜手术的优势与现代微创外科的理念于一体,它在确保手术效果的基础上集中体现了微创、加速康复外科、功能外科、"无疤"等理念的特点。本文主要就国内外各中心开展NOSES技术在结直肠外科诊治开展中的相关经验、心得和体会进行综述。 相似文献
68.
69.
70.